Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

• DOI: 10.1038/s41408-021-00528-x
• Publication Date: 2021-07-30T18:17:26Z
• Authors: H. Parry; G. McIlroy; R. Bruton; M. Ali; C. Stephens; S. Damery; A. Otter; T. McSkeane; H. Rolfe; S. Faustini; N. Wall; P. Hillmen; G. Pratt; S. Paneesha; J. Zuo; A. Richter; P. Moss
• Keywords: Immunosuppression

B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines offer the potential for protection against severe infection but relatively little known regarding profile of antibody response first or second vaccination. We studied spike-specific responses and/or vaccination in 299 CLL compared healthy donors. 286 underwent extended interval (10-12 week) 154 received BNT162b2 mRNA vaccine 145 ChAdOx1. Blood samples were taken either by venepuncture as dried blood spots on filter paper. Spike-specific detectable 34% after one (n = 267) to 94% donors titres 104-fold lower patient group. Antibody 75% 55), 100% donors, although remained lower. Multivariate analysis showed that current treatment BTK inhibitors IgA deficiency independently failure generate an vaccine. This work supports need optimisation strategy including utility booster vaccines.